Aptorum Group has initiated IND-Enabling Studies for its ALS-4 Small Molecule Candidate for the Treatment of Infections Caused by Staphylococcus Aureus including MRSA
HONG KONG, Sep, 10 2019 - (ACN Newswire) - Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces that it has initiated investigational new drug (IND)-enabling studies for ALS-4, a small drug molecule candidate indicated for the treatment of infections caused by Staphylococcus aureus (or "S. aureus") including methicillin-resistant Staphylococcus aureus (MRSA, i.e., one of the commonly known "super-bugs") based on a novel anti-virulence approach.
The ALS-4 candidate has been progressing well and the first series of GLP toxicology studies have been completed through an appointed North American based contract research organization (CRO). In particular, ALS-4 candidate did not show any mutagenicity in the in vitro Ames tests. ALS-4 development is on track and the company targets to submit the related IND in the first half year of 2020 and a hybrid Phase 1 clinical study is currently planned in North America with both healthy volunteers and patients to obtain preliminary efficacy readout.
S. aureus is a bacteria which is a leading cause of blood, lung, skin, bone and device-related infections, as well as toxin-related diseases1. It is estimated that patients with S. aureus bacteremia have an average mortality rate of 30%2 and that it is responsible for causing more deaths than AIDS, tuberculosis and viral hepatitis combined3. MRSA and vancomycin-intermediate and resistant S. aureus have also been classified by the World Health Organization (WHO) as high priority pathogens for research and development4.
ALS-4 is a small molecule drug candidate that is believed to inhibit dehydrosqualene desaturase of S. aureus (incl. MRSA) which is involved in the generation of staphyloxanthin, a commonly visible "golden pigment" covering the bacteria and is primarily responsible for the bacteria's resistance to attack from reactive oxygen species (ROS) deployed by phagocytic cells and neutrophils5. On this basis, ALS-4 is not bactericidal and through inhibiting the production of staphyloxanthin, S. aureus becomes highly susceptible to the host's immune clearance. ALS-4 deploys a novel approach towards the treatment of bacterial infection which is significantly different from the bactericidal approach found in most current antibiotics that are experiencing increasing drug resistance issues.
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group is pursuing therapeutic projects in neurology, infectious diseases, gastroenterology, oncology and other disease areas.
For more information about Aptorum Group, please visit www.aptorumgroup.com.
Disclaimer and Forward-Looking Statements
This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," or "continue," or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company's anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group's Form 20-F and other filings that Aptorum Group may make with the SEC in the future. As a result, the projections included in such forward-looking statements are subject to change. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
1 Clin Microbiol Rev. 2015 Jul;28(3):603-61
2 Clin Microbiol Rev. 2012 Apr;25(2):362-86
3 Van Hal et al. Clin Microbiol Rev 2012
5 mBio 2017 8(5): e01224-17
Tel: +852 2117 6611
Email: [email protected]
Tel: + 852 2117 6611
Email: [email protected]
Kindly refer to the below link for our corporate presentation:
You may also refer to the below for our one-pager presentation:
Source: Aptorum Group Limited
Sectors: Daily Finance, Daily News, BioTech, HealthCare
Copyright ©2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
More Latest Release >>
SDK Receives Award for Used-Plastic Chemical Recycling Business
Feb 28, 2020 16:00 JST
SDK Announces Progress Towards the Tender Offer for Shares of Hitachi Chemical Company, Ltd. (Securities Code 4217)
Feb 28, 2020 16:00 JST
NEC's Unified Communications Platform "UNIVERGE SV Series" Reaches 500,000 Shipments
Feb 28, 2020 14:32 JST
Mitsubishi Corporation and Chubu Electric Power Consortium Named Preferred Bidder for Offshore Transmission Asset in the UK
Feb 28, 2020 07:47 JST
Mazda Production and Sales Results for January 2020
Feb 27, 2020 14:03 JST
Toyota Updates Results for January 2020
Feb 27, 2020 13:35 JST
NEC Releases "Open & Virtualized RAN" White Paper
Feb 27, 2020 12:15 JST
Hitachi and Chulalongkorn University Agree on a Cooperative Relationship for Social Innovation in Thailand
Feb 27, 2020 09:44 JST
Mitsubishi Aircraft Corporation and Mitsubishi Heavy Industries Aero Engines Celebrate First Flight of First GTF Engine Produced in Japan
Feb 27, 2020 09:32 JST
NEC Partners with Juniper Networks to Enable Telefonica Chile's IP Network Fusion Project
Feb 26, 2020 16:33 JST
Lexus' Electrification Drives Sensory Experience at Milan Design Week 2020
Feb 25, 2020 18:27 JST
4 Sharp Products Win 2020 iF Design Award
Feb 25, 2020 17:37 JST
Mitsubishi Corporation and CRISP HD Agree to Business Alliance and Acquisition of Third-Party Shares
Feb 25, 2020 15:16 JST
Double Podium for TOYOTA GAZOO Racing in Austin
Feb 25, 2020 09:41 JST
Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China
Feb 25, 2020 09:10 JST
The Closure of Automobile Production in the Philippines
Feb 22, 2020 18:00 JST
Eisai Receives the President's Award of the Japan Techno-Economics Society at the 8th Technology Management and Innovation Awards
Feb 21, 2020 17:55 JST
MHPS Receives 12 Year Maintenance Service Extension for the BLCP Power Station in Thailand
Feb 21, 2020 16:07 JST
Toyota and Toyota Industries Jointly Develop New Battery for Hybrid Electric Vehicles
Feb 20, 2020 14:27 JST
NEC and Accedian partner globally to address network performance visibility challenges and predictive analytics requirements
Feb 20, 2020 13:03 JST